KalVista Says Sebetralstat's Orally Disintegrating Formulation At Par With Film-Coated Version For HAE Attacks

Vandana Singh
1 min read
0
In this article:

  • KalVista Pharmaceuticals Inc (NASDAQ: KALV) announced phase 1 data for an orally disintegrating tablet (ODT) formulation for its lead compound sebetralstat.

  • Sebetralstat is currently being developed in the phase 3 KONFIDENT trial as a potential on-demand treatment for hereditary angioedema (HAE) attacks.

  • The phase 1 trial enrolled 36 healthy adult volunteers to compare the pharmacokinetics (PK) of sebetralstat following the administration of ODT and the current film-coated tablets in healthy adult volunteers.

  • Also Read: KalVista Shares Plunge After Ending KVD824 HAE Trial Over Elevated Liver Enzymes In Patients.

  • Data from the study showed that the ODT tablet formulation has a similar PK profile to the film-coated version currently in development.

  • Based upon these results, KalVista intends to continue developing the formulation to make it available as soon as possible after the sebetralstat anticipated launch in the U.S.

  • KalVista expects data from the KONFIDENT study using the film-coated tablets will be available in the second half of 2023, to support a planned marketing application filing in the first half of 2024.

  • Price Action: KALV shares are down 1.08% at $5.06 on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories